|
|
|
|
|
|
By Olivier Laczka, Ph.D., Noxopharm | Significant caveats with the current base modification approach for mRNA vaccines still remain and need to be addressed. This article looks at activation of innate immunity, overcoming the limitations of pseudouridine, novel 3-base oligonucleotides, and more. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIFE SCIENCE LEADER MAGAZINE |
|
|
|
Have you heard of Life Science Leader? Check it out today for access to candid interviews with top-tier executives on how they do business. |
|
|